trending Market Intelligence /marketintelligence/en/news-insights/trending/2ZEbUtUymdHaHT8ZBW7f2g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Sarepta's previously rejected Duchenne drug gets US FDA accelerated approval

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sarepta's previously rejected Duchenne drug gets US FDA accelerated approval

The U.S. Food and Drug Administration granted accelerated approval to Sarepta Therapeutics Inc.'s Vyondys 53 injection to treat Duchenne muscular dystrophy after previously rejecting the drug.

DMD is a genetic disorder characterized by progressive muscle degeneration and weakness.

Vyondys 53 was approved to treat DMD patients with confirmed mutation of the dystrophin gene amenable to exon 53 skipping. According to the regulator, the drug is the first treatment for this specific subtype of the disease, which affects about 8% of DMD patients.

Sarepta is conducting a confirmatory trial, dubbed Essence, to confirm the drug's predicted clinical benefit. The company expects the study, which is enrolling patients, to be completed by 2024.

In August, the FDA issued a complete response letter for Sarepta's new drug application for Vyondys 53, or golodirsen, injection. The regulator was concerned about the risk of infections related to intravenous infusion ports and kidney-related toxicity seen in preclinical models of the injection.

Following the rejection, the Cambridge, Mass.-based company appealed the FDA's decision and resubmitted the NDA.

Sarepta's Exondys 51 also treats DMD but targets a different section of the gene compared to Vyondys 53.

Sarepta's stock was up by 27.9% to $128.5 as of 7:39 p.m. ET on Dec 12.